Liquid biopsy: current technology and clinical applications.
Nikanjam M, Kato S, Kurzrock R. · 2022
Read Liquid biopsy: current technology and clinical applications. by Nikanjam M, Kato S, Kurzrock R. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9465933.txt.
Introduction
Nikanjam, Kato, and Kurzrock review liquid biopsy tools and their clinical uses in cancer care. A liquid biopsy reads tumor signals from blood and other fluids. Targets include cell-free DNA, tumor DNA, and whole circulating tumor cells. The method is far less invasive than tissue biopsy.
The authors sort the lab methods for each target type. Droplet digital PCR and deep sequencing lead the DNA side. Cell capture by markers or physical traits leads the cell side. Uses span early detection and prognosis checks. Serial samples can track response and resistance to targeted drugs and immunotherapy. Hard to reach tumors can be profiled this way too. Limits include scant shed material and confounding by clonal blood changes. Future work may add fluids like urine and spinal fluid.
Catalog record
| CREATOR | Nikanjam M, Kato S, Kurzrock R. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Liquid biopsy: current technology and clinical applications By Mina Nikanjam, Shumei Kato, Razelle Kurzrock Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-022-01351-y ABSTRACT Abstract Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). CTCs have been isolated using biomarker-based cell capture, and positive or negative enrichment based on biophysical and other properties. ctDNA/cfDNA and CTCs are being exploited in a variety of clinical applications: differentiating unique immune checkpoint blockade response patterns using serial samples; predicting immune checkpoint blockade response based on baseline liquid biopsy characteristics; predicting response and resistance to targeted therapy and chemotherapy as well as immunotherapy, including CAR-T cells, based on serial sampling; assessing shed DNA from multiple metastatic sites; assessing potentially actionable alterations; analyzing prognosis and tumor burden, including after surgery; interrogating difficult-to biopsy tumors; and detecting cancer at early stages. The latter can be limited by the small amounts of tumor-derived components shed into the circulation; furthermore, cfDNA assessment in all cancers can be confounded by clonal hematopoeisis of indeterminate potential, especially in the elderly. CTCs can be technically more difficult to isolate that cfDNA, but permit functional assays, as well as evaluation of CTC-derived DNA, RNA and proteins, including single-cell analysis. Blood biopsies are less invasive than tissue biopsies and hence amenable to serial collection, which can provide critical molecular information in real time. In conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes. Keywords: Liquid biopsy, CTC, cfDNA, ctDNA, Precision medicine BACKGROUND Liquid “biopsy” technology, which enables the molecular interrogation of liquid samples (usually blood), has advanced at breathtaking speed, facilitating its routine clinical use in patients with cancer, and rapidly expanding research capabilities that are uncovering the basis of malignant growth. Liquid biopsies are minimally invasive and provide a methodology for obtaining tumor-derived information from body fluids. There are many body fluids that can be biopsied; however, the most commonly used fluid is blood (Fig. 1A, C). [Figure: A Types of liquid biopsies. Liquid biopsy is most commonly obtained via blood sampling, but can also be derived from urine, CSF, ascites fluid, and pleural fluid. cfDNA/ctDNA, CTCs, RNA, and extracellular vesicles can be isolated from these fluids. Protein expression and methylation patterns can also be assessed with liquid biopsy. Boxes represent examples of fluids biopsied and circles represent examples of materials isolated/evaluated. B Clinical applications of liquid biopsies. Liquid biopsies (cfDNA/ctDNA and CTCs) have been utilized for a variety of purposes as noted. C Examples of types of liquid biopsies, material isolated/analyzed, and clinical applications. Liquid biopsy is most commonly obtained via blood sampling, but can also be derived from a variety of other fluids. cfDNA/ctDNA and CTCs are the most commonly isolated and analyzed materials. cfDNA: cell-free DNA, ctDNA: circulating tumor DNA, CTCs: circulating tumor cells] Circulating extracellular nucleic acids (cell-free DNA; cfDNA) and circulating tumor DNA (ctDNA) can be isolated from the blood. cfDNA is DNA freely circulating in the blood, which may or may not be of tumor origin, whereas ctDNA is of tumor origin. Circulating tumor cells (CTCs) can also be isolated from the blood. These are cells that are shed into the blood from tumors and usually only last for 1–2.5 h in the circulation prior to destruction by the immune system, but a small fraction can survive and seed distant metastatic sites. ctDNA/cfDNA and CTCs can be assayed using next-generation sequencing (NGS) [1, 2]. Protein and RNA CTC content can also be assessed, as well as functional CTC characteristics, which can guide the use of potential therapeutic compounds. Differences between ctDNA/cfDNA and CTCs are shown in Table 1 [3, 4]. [Table: Comparison of ctNDA/cfDNA and CTCs [1–4]] This review provides a summary of current technologies for detecting ctDNA/cfDNA and CTCs from liquid biopsies, along with clinical applications and future directions. Technologies for ctDNA/cfDNA detection The following techniques are among those that have been deployed to evaluate ctDNA/cfDNA: droplet digital polymerase chain reaction (ddPCR), beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). ddPCR can detect as low as 0.01–1.0% of genomic material and is useful for identifying potentially rare mutations and calculating copy number variants [5, 6]. However, it can only be used to evaluate the presence of characterized sequences. Similarly BEAMing is a relatively sensitive and inexpensive method of screening for known mutations. It combines PCR with flow cytometry and can detect alterations at levels as low as 0.01% with excellent concordance to tissue testing [6] [38, 43]. CAPP-Seq identifies alterations in ctDNA/cfDNA using large genomic libraries and individual patient sample sequence signatures. It statistically assesses well-characterized tumor alterations with DNA oligonucleotides to find patient-specific alterations. It can identify multiple mutations in patients with the same type of cancer and assess tumor heterogeneity. It was previously shown to be capable of identifying tumor burdens prior to medical imaging. It can identify many major mutation types including insertions, deletions, single nucleotide variants, copy variants, and rearrangements, but cannot identify fusions [6, 7]. Tam-Seq allows for a very specific and sensitive analysis (~ 97%) and can detect DNA levels as low as 2% by using primers to tag and identify genomic sequences. It has a high sequencing flux, reduced sequencing time and cost, and can simultaneously sequence millions of DNA molecules. However, the desired sequence needs to be previously characterized for the methodology to work [6, 8]. Whole exome sequencing provides characterization and analysis of all present tumor mutations, thus can identify potential oncogenes and tumor suppressor genes. However, its sensitivity may be lower than other methods since it includes exomic alterations. It is characterized by low cost and high yield [6, 9]. Whole genome sequencing evaluates the entire tumor genome to determine characterized and deleterious alterations along with variants of unknown significance. It has great potential for a comprehensive evaluation of all tumor mutations, but is limited by quality assurance, ethical issues, time, and cost. Interpretation of results can be difficult outside of specialized centers[9, 10]. WGBS-Seq is the gold standard in DNA methylation analysis. It provides a single cytosine measurement and has very high accuracy. While it can discover partially methylated domains in cancer cells, DNA may exist in varying degrees of degradation and thus this method can have reduced sensitivity [11, 12]. Technologies for CTC detection The following methods have been used to isolate CTCs: